Thank You for Visiting DIMA Biotech at PEGS & CAS 2025!
We had a fantastic time connecting with researchers, partners, and customers at PEGS Boston and the CAS 2025 Annual Meeting this May. Thank you to everyone who stopped by our booth, attended our talks, or picked up our materials—it was great to meet so many of you in person!
As a follow-up, we’ve created this page to share key resources, highlights, and moments from both conferences. Whether you’d like to revisit our materials or explore our latest innovations, everything is just a click away.
Explore Our Technologies & Platforms
Download our latest brochures, product highlights, and technical posters:
DIMA Highlight
Lead Antibody Molecules
Synthetic Nanodisc
Scan code download
About DIMA BIOTECH
CAS Meeting Poster
Conference Highlights
Check out some snapshots and videos from our time at PEGS and CAS:
Browse our categories
Latest News
CCR1: An Emerging Target for Immune Regulation and Drug Development
CCR1 (C-C motif chemokine receptor 1) is a G protein-coupled receptor (GPCR) involved in inflammatory responses [...]
Jun
New Product Launch | DT3C Protein: A Powerful Tool for Validating Antibody Internalization
Are you developing antibody-drug conjugates (ADCs)? Are you seeking a reliable and standardized method to [...]
Jun
DIMA Membrane Proteins Empower Nobel Team’s Breakthrough in GPCR Drug Discovery
DIMA’s CXCR4-Nanodisc Empowers New Preprint from David Baker, which is entitled "De novo design of miniprotein agonists [...]
FLT3 | A Key Therapeutic Target in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a complex and highly heterogeneous hematologic malignancy closely associated with [...]
May
Dual-Payload ADCs: The Next Big Thing in the ADC Arena
Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, [...]
Apr
NPY Receptor Family: “New Targets” and “Old Challenges” in Disease Treatment
In the drug development efforts targeting complex diseases such as neuropsychiatric disorders, metabolic dysregulation, and [...]
Apr
Popular Targets in the Bispecific ADC Pipeline
At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such [...]
Apr
An Invitation|Welcome to meet DIMA BIOTECH in Boston in May
DIMA BIOTECH will showcase over 5,000+ in-stock lead mAbs and 500+ in-stock Nanodisc at 2025 [...]
Apr
What’s Next?
We’re excited to continue supporting your research through:
Currently, we offer over 500 in-stock Nanodisc products, covering more than 200 membrane protein targets, with a variety of tag options available (such as Flag, MBP, Strep, etc.) to meet diverse experimental needs. In addition to our catalog products, we also provide customized services, including biotin labeling, protein affinity binding analysis(SPR), and more, offering flexible support for your research workflows.
Our Nanodiscs provide a stable, native-like lipid bilayer environment for membrane proteins, making them ideal for applications such as membrane protein stabilization, structural biology(Cryo-EM), ligand screening, and antibody discovery.
Click to read our latest blog about Optimizing GPCR Expression and Purification.
At present, DIMA has developed B cell seed libraries and the corresponding pilot antibody molecules for around 500+ targets for blood tumor, immune checkpoints and solid tumors. All targets have human-rabbit chimeric antibodies, and 50+ targets have completed humanization antibodies developed by our DiLibrary™ display platform.
Contact US
If you missed us at the show or want to follow up, feel free to reach out—we’d love to hear from you!